Zubrin

RSS

Withdrawn

This medicine's authorisation has been withdrawn

tepoxalin
MedicineVeterinaryWithdrawn

Dutch is available via eTranslation, the European Commission's machine translation service.

Translate to Dutch | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The market authorisation for Zubrin has been withdrawn at the request of the marketing-authorisation holder.

español (ES) (511.13 kB - PDF)

Bekijk

čeština (CS) (595.78 kB - PDF)

Bekijk

dansk (DA) (510.17 kB - PDF)

Bekijk

Deutsch (DE) (513.33 kB - PDF)

Bekijk

eesti (ET) (510.33 kB - PDF)

Bekijk

ελληνικά (EL) (664.57 kB - PDF)

Bekijk

français (FR) (513.24 kB - PDF)

Bekijk

italiano (IT) (511.22 kB - PDF)

Bekijk

latviešu (LV) (581.56 kB - PDF)

Bekijk

lietuvių (LT) (536.1 kB - PDF)

Bekijk

magyar (HU) (589.67 kB - PDF)

Bekijk

Nederlands (NL) (510.07 kB - PDF)

Bekijk

polski (PL) (597.7 kB - PDF)

Bekijk

português (PT) (511.85 kB - PDF)

Bekijk

slovenčina (SK) (569.98 kB - PDF)

Bekijk

slovenščina (SL) (589.46 kB - PDF)

Bekijk

suomi (FI) (510 kB - PDF)

Bekijk

svenska (SV) (509.65 kB - PDF)

Bekijk

Product information

български (BG) (1.39 MB - PDF)

Bekijk

español (ES) (354.35 kB - PDF)

Bekijk

čeština (CS) (876.13 kB - PDF)

Bekijk

dansk (DA) (361.88 kB - PDF)

Bekijk

Deutsch (DE) (380.8 kB - PDF)

Bekijk

eesti (ET) (353.43 kB - PDF)

Bekijk

ελληνικά (EL) (1.1 MB - PDF)

Bekijk

français (FR) (363.75 kB - PDF)

Bekijk

italiano (IT) (369.61 kB - PDF)

Bekijk

latviešu (LV) (919.36 kB - PDF)

Bekijk

lietuvių (LT) (1.36 MB - PDF)

Bekijk

magyar (HU) (1.04 MB - PDF)

Bekijk

Malti (MT) (898.07 kB - PDF)

Bekijk

Nederlands (NL) (369.61 kB - PDF)

Bekijk

polski (PL) (696.28 kB - PDF)

Bekijk

português (PT) (370.61 kB - PDF)

Bekijk

română (RO) (907.36 kB - PDF)

Bekijk

slovenčina (SK) (1.1 MB - PDF)

Bekijk

slovenščina (SL) (738.16 kB - PDF)

Bekijk

suomi (FI) (347.73 kB - PDF)

Bekijk

svenska (SV) (339.08 kB - PDF)

Bekijk

Íslenska (IS) (608.9 kB - PDF)

Bekijk

norsk (NO) (663.7 kB - PDF)

Bekijk
Latest procedure affecting product information:IB/0032
02/02/2012

español (ES) (243.72 kB - PDF)

Bekijk

čeština (CS) (768.39 kB - PDF)

Bekijk

dansk (DA) (243.34 kB - PDF)

Bekijk

Deutsch (DE) (460.26 kB - PDF)

Bekijk

eesti (ET) (15.67 kB - PDF)

Bekijk

ελληνικά (EL) (320.74 kB - PDF)

Bekijk

français (FR) (243.6 kB - PDF)

Bekijk

italiano (IT) (243.26 kB - PDF)

Bekijk

latviešu (LV) (321.63 kB - PDF)

Bekijk

lietuvių (LT) (304.46 kB - PDF)

Bekijk

magyar (HU) (308.89 kB - PDF)

Bekijk

Malti (MT) (322.75 kB - PDF)

Bekijk

Nederlands (NL) (243.75 kB - PDF)

Bekijk

polski (PL) (280.86 kB - PDF)

Bekijk

português (PT) (243.78 kB - PDF)

Bekijk

slovenčina (SK) (281.56 kB - PDF)

Bekijk

slovenščina (SL) (278.91 kB - PDF)

Bekijk

suomi (FI) (240.48 kB - PDF)

Bekijk

svenska (SV) (244 kB - PDF)

Bekijk

Product details

Name of medicine
Zubrin
Active substance
tepoxalin
International non-proprietary name (INN) or common name
tepoxalin
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) code
QM01AE92

Pharmacotherapeutic group

Musculo-skeletal system

Therapeutic indication

Reduction of inflammation and relief of pain caused by acute and chronic musculoskeletal disorders.

Authorisation details

EMA product number
EMEA/V/C/000057
Marketing authorisation holder
Intervet International BV

Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Marketing authorisation issued
13/03/2001
Revision
13

Assessment history

This page was last updated on

Share this page